Coherus Oncology Statistics
Total Valuation
CHRS has a market cap or net worth of $244.32 million. The enterprise value is $126.56 million.
Important Dates
The last earnings date was Monday, March 9, 2026, after market close.
| Earnings Date | Mar 9, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CHRS has 149.89 million shares outstanding. The number of shares has increased by 2.26% in one year.
| Current Share Class | 149.89M |
| Shares Outstanding | 149.89M |
| Shares Change (YoY) | +2.26% |
| Shares Change (QoQ) | +3.56% |
| Owned by Insiders (%) | 10.17% |
| Owned by Institutions (%) | 37.73% |
| Float | 134.62M |
Valuation Ratios
The trailing PE ratio is 1.14.
| PE Ratio | 1.14 |
| Forward PE | n/a |
| PS Ratio | 5.79 |
| Forward PS | 2.65 |
| PB Ratio | 3.24 |
| P/TBV Ratio | 16.54 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | 0.75 |
| EV / Sales | 3.00 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.47, with a Debt / Equity ratio of 0.89.
| Current Ratio | 1.47 |
| Quick Ratio | 1.36 |
| Debt / Equity | 0.89 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -19.60 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -31.20% |
| Return on Invested Capital (ROIC) | -78.20% |
| Return on Capital Employed (ROCE) | -149.57% |
| Weighted Average Cost of Capital (WACC) | 10.75% |
| Revenue Per Employee | $286,884 |
| Profits Per Employee | $1.14M |
| Employee Count | 147 |
| Asset Turnover | 0.12 |
| Inventory Turnover | 3.74 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +66.33% in the last 52 weeks. The beta is 1.09, so CHRS's price volatility has been similar to the market average.
| Beta (5Y) | 1.09 |
| 52-Week Price Change | +66.33% |
| 50-Day Moving Average | 1.80 |
| 200-Day Moving Average | 1.35 |
| Relative Strength Index (RSI) | 42.06 |
| Average Volume (20 Days) | 1,999,491 |
Short Selling Information
The latest short interest is 27.66 million, so 18.45% of the outstanding shares have been sold short.
| Short Interest | 27.66M |
| Short Previous Month | 29.61M |
| Short % of Shares Out | 18.45% |
| Short % of Float | 20.55% |
| Short Ratio (days to cover) | 11.74 |
Income Statement
In the last 12 months, CHRS had revenue of $42.17 million and earned $168.02 million in profits. Earnings per share was $1.43.
| Revenue | 42.17M |
| Gross Profit | 28.36M |
| Operating Income | -176.43M |
| Pretax Income | -183.12M |
| Net Income | 168.02M |
| EBITDA | -172.51M |
| EBIT | -176.43M |
| Earnings Per Share (EPS) | $1.43 |
Full Income StatementBalance Sheet
The company has $172.13 million in cash and $54.36 million in debt, with a net cash position of $117.76 million or $0.79 per share.
| Cash & Cash Equivalents | 172.13M |
| Total Debt | 54.36M |
| Net Cash | 117.76M |
| Net Cash Per Share | $0.79 |
| Equity (Book Value) | 61.01M |
| Book Value Per Share | 0.50 |
| Working Capital | 66.32M |
Full Balance SheetCash Flow
| Operating Cash Flow | -138.51M |
| Capital Expenditures | n/a |
| Free Cash Flow | -138.51M |
| FCF Per Share | -$0.92 |
Full Cash Flow StatementMargins
Gross margin is 67.24%, with operating and profit margins of -418.37% and 398.43%.
| Gross Margin | 67.24% |
| Operating Margin | -418.37% |
| Pretax Margin | -434.23% |
| Profit Margin | 398.43% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CHRS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.26% |
| Shareholder Yield | -2.26% |
| Earnings Yield | 68.77% |
| FCF Yield | -56.69% |
Analyst Forecast
The average price target for CHRS is $5.51, which is 238.04% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $5.51 |
| Price Target Difference | 238.04% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 58.67% |
| EPS Growth Forecast (5Y) | -37.89% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CHRS has an Altman Z-Score of -8.87 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -8.87 |
| Piotroski F-Score | 5 |
